Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.265,24
0,42%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Eiger BioPharmaceuticals Inc (EIGR) Eiger BioPharmaceuticals Inc (EIGR) Notizie

Eiger BioPharmaceuticals Inc

EIGR
1,725
0,00 (0,00%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/4/202417:12GLOBEEiger BioPharmaceuticals Files for Voluntary Chapter 11..
11/3/202421:03EDGAR2Form 8-K - Current report
24/1/202422:59EDGAR2Form 8-K - Current report
18/1/202423:49PRNUSEiger and Partner, AnGes, Receive Approval for Zokinvy®..
08/1/202413:00EDGAR2Form 8-K - Current report
04/1/202414:45EDGAR2Form 8-K - Current report
04/1/202414:00PRNUSEiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse..
11/12/202322:01EDGAR2Form DEF 14A - Other definitive proxy statements
04/12/202312:01EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202322:02EDGAR2Form PRE 14A - Other preliminary proxy statements
24/11/202312:01EDGAR2Form SC 13D - General statement of acquisition of beneficial..
13/11/202322:01EDGAR2Form 8-K - Current report
09/11/202322:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:14EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSEiger BioPharmaceuticals Reports Third Quarter 2023..
03/11/202302:54EDGAR2Form SC 13D/A - General statement of acquisition of..
03/11/202302:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202321:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/10/202322:29EDGAR2Form SC 13D - General statement of acquisition of beneficial..
28/9/202322:54EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/9/202323:17DJNEiger BioPharmaceuticals to Discontinue Chronic Hepatitis..
12/9/202322:42EDGAR2Form 8-K - Current report
12/9/202322:05PRNUSEiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon..
06/9/202303:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202303:35EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202322:05PRNUSEiger BioPharmaceuticals to Present at H.C. Wainwright 25th..
15/8/202312:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/8/202322:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:09EDGAR2Form 8-K - Current report
14/8/202322:05PRNUSEiger BioPharmaceuticals Reports Second Quarter 2023..
28/7/202322:17EDGAR2Form 8-K - Current report
07/7/202322:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/7/202323:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202322:16EDGAR2Form 8-K - Current report
29/6/202314:00PRNUSEiger BioPharmaceuticals to Focus on Metabolic Diseases with..
28/6/202322:05PRNUSEiger BioPharmaceuticals to Host Business Update Call..
11/5/202322:00PRNUSEiger BioPharmaceuticals Reports First Quarter 2023..
Apertura: Min: Max:
Chiusura: 1,725

La tua Cronologia

NASDAQ
EIGR
Eiger BioPharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network